Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report describes a case where the JAK inhibitor tofacitinib led to hair regrowth in a patient with alopecia totalis but also worsened facial acne, highlighting a unique adverse effect.

This review discusses the genetics, therapy, and prognosis of childhood alopecia areata, noting that while current treatments are not curative, new modalities may improve future outcomes; it reports no new clinical results.

This review discusses recent literature on retinoids, platelet-rich plasma, and JAK inhibitors for hair loss treatments without offering new clinical results.

This study explored peripheral blood immune dysregulation in alopecia areata through single-cell analyses, identifying systemic changes linked to disease severity and key signaling roles for monocytes, NK cells, and memory T cells, suggesting potential therapeutic targets.

This consensus from the Taiwanese Dermatological Association suggests that for mild to moderate alopecia areata, first-line treatments may include topical or intralesional corticosteroids, possibly with topical minoxidil, while severe cases might require systemic corticosteroids or Janus kinase inhibitors.

In this case report, a severe case of pediatric alopecia areata was treated with topical ruxolitinib, a Janus kinase inhibitor, highlighting the limited but promising evidence for this treatment in children.

This study reported that dupilumab, an FDA-approved biologic, is a safe and effective first-line systemic treatment for children with moderate-to-severe atopic dermatitis, showing sustained skin improvement and itch reduction, with injection site reactions and conjunctivitis as potential side effects.

In this retrospective analysis, the authors reported that off-label tofacitinib treatment in 35 alopecia areata patients demonstrated safety, with no serious adverse events, and effectiveness, with 83.9% showing significant scalp regrowth and 32.3% achieving near total or total regrowth.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

This study reports significant hair regrowth in 11 patients with severe alopecia areata following longstanding treatment with oral tofacitinib and also highlights successful treatment using topical tofacitinib cream in one case.

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

Many patients with alopecia areata relapse after stopping tofacitinib.

This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.

This study found that online materials about alopecia areata and its treatments are generally difficult to understand, with information on JAK inhibitors being particularly challenging, highlighting a need for clearer educational resources for patients.

In this case report, researchers identified a potential adverse skin reaction, called SDRIFE or Baboon syndrome, caused by the drug tofacitinib in a 19-year-old woman being treated for alopecia subtotalis, leading the authors to recommend discontinuation of the drug.

This article discusses barriers to obtaining JAK inhibitor therapy for patients with alopecia areata and highlights that racial inequities may worsen these difficulties; it calls for further advocacy to improve access.

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

This review discusses the biology and pathology of hair growth, exploring novel therapies like sublingual minoxidil and Janus kinase inhibitors, but reports no new clinical data.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

This study reviews the types of alopecia associated with lupus erythematosus and discusses treatment challenges, highlighting that non-scarring alopecia is specific to systemic lupus while chronic cutaneous lupus can cause scarring alopecia, with topical corticosteroids and oral antimalarials as primary treatments for cutaneous lupus erythematosus.

This case report suggests that JAK inhibitors like tofacitinib may effectively treat alopecia in patients with complex cases involving both rheumatological and dermatological conditions.

This study found that topical curcumin can initiate hair growth in mice by acting as a JAK inhibitor but could not fully reverse alopecia areata, likely due to insufficient penetration to deeper skin layers.

This retrospective cohort study found no significant association between Janus kinase inhibitors and increased malignancy risk in alopecia areata patients, but traditional immunosuppressants were linked to higher risks of internal and hematologic malignancies.

This study suggests that Janus kinase inhibitors may offer a potential treatment option for refractory lichen planopilaris and frontal fibrosing alopecia, showing positive response rates between 42% and 100%, though evidence quality is low.

This review discusses the role of Janus-kinase inhibitors in treating severe atopic dermatitis and alopecia areata, presenting case studies that show their efficacy and calling for further research on long-term effectiveness and safety.

This review discusses educational activities for dermatologists on diagnosing and managing different types of hair loss and reports no new clinical results; it emphasizes improving clinical skills for alopecia treatment.

This review discusses the potential role of a PADI3 gene variant in central centrifugal cicatricial alopecia among African-American women but reports no new clinical results.

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

This review discusses the evaluation, diagnosis, and management of beard alopecia areata and reports no new clinical results, though it highlights recent treatment advances with janus kinase inhibitors.